ID   BC-3C
AC   CVCL_1958
SY   BC3c
DR   CLO; CLO_0001893
DR   ArrayExpress; E-MTAB-2770
DR   BioSample; SAMN03473550
DR   BioSample; SAMN10988581
DR   CCLE; BC3C_URINARY_TRACT
DR   Cell_Model_Passport; SIDM01523
DR   Cosmic; 1046690
DR   Cosmic; 1285112
DR   Cosmic; 1286004
DR   Cosmic; 2050437
DR   Cosmic; 2057442
DR   Cosmic; 2444240
DR   Cosmic; 2685938
DR   DepMap; ACH-000593
DR   DSMZ; ACC-450
DR   GEO; GSM886873
DR   GEO; GSM887938
DR   IARC_TP53; 30018
DR   LiGeA; CCLE_276
DR   PharmacoDB; BC3C_80_2019
DR   Wikidata; Q54795193
RX   PubMed=9794224;
RX   PubMed=22460905;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=31068700;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Doubling time: ~25-30 hours (DSMZ).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=1.78%; Native American=0.28%; East Asian, North=4.58%; East Asian, South=0%; South Asian=3.73%; European, North=37.13%; European, South=52.49% (PubMed=30894373).
ST   Source(s): DSMZ
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 9
ST   D16S539: 11,13
ST   D5S818: 11,13
ST   D7S820: 11
ST   TH01: 6,9
ST   TPOX: 8
ST   vWA: 15,16
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 20
//
RX   PubMed=9794224; DOI=10.1007/s11626-998-0068-z;
RA   Pratsinis H., Saetta A., Gagos S., Davaris P.;
RT   "Isolation and characterization of a novel bladder cancer cell line:
RT   inhibition by epidermal growth factor.";
RL   In Vitro Cell. Dev. Biol. Anim. 34:722-728(1998).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//